SLC27A5 and metabolic dysfunction-associated steatotic liver disease: Liver studies have shown that Pue has a dual inhibitory effect on CD36 and fatty acid transporter protein 5 (FATP5), which significantly reduces lipid deposition associated with NAFLD (55).